ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Ann Thorac Surg 2009;87:1203-1204. doi:10.1016/j.athoracsur.2009.02.034
© 2009 The Society of Thoracic Surgeons
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Paul S. Lee
Terrence M. Yau
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lee, P. S.
Right arrow Articles by Yau, T. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lee, P. S.
Right arrow Articles by Yau, T. M.
Related Collections
Right arrow Molecular biology
Right arrowRelated Article

Original Articles: Adult Cardiac

Invited Commentary

Paul S. Lee, BSc, Terrence M. Yau, MD, FRCSC

Division of Cardiovascular Surgery, Toronto General Hospital, 4N-470, 200 Elizabeth St, Toronto, ON M5G 2C4, Canada

(Email: terry.yau@uhn.on.ca).

The first 20% of the full text of this article appears below.

In recent years, stem cell therapy has received considerable attention as a novel therapeutic option for refractory congestive heart failure. Although the mechanisms through which these cells elicit functional improvement are yet to be fully determined, recent studies suggest that paracrine effects, rather than direct trans-differentiation of donor cells into cardiomyocytes, may predominate in augmenting postinfarction cardiac function.

Progress in cell therapy, however, is hampered by suboptimal engraftment of donor cells into the myocardium, related to the extensive cell death that ensues from the hostile milieu into which the donor cells are introduced. This problem has stimulated further investigation of the use of bioengineered scaffolds as cell delivery vehicles, with the hope that these constructs may . . . [Full Text of this Article]


Related Article

Cell Delivery: Intramyocardial Injections or Epicardial Deposition? A Head-to-Head Comparison
Hadhami Hamdi, Akira Furuta, Valérie Bellamy, Alain Bel, Etienne Puymirat, Séverine Peyrard, Onnik Agbulut, and Philippe Menasché
Ann. Thorac. Surg. 2009 87: 1196-1203. [Abstract] [Full Text] [PDF]





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2009 by The Society of Thoracic Surgeons.